AstraZeneca Acknowledges Rare Blood Clot Risk with Covishield Vaccine
The pharmaceutical giant confirms the rare side effect in court documents but emphasizes the overall safety and benefits of the vaccine.
- AstraZeneca has officially admitted that its COVID-19 vaccine, Covishield, can cause Thrombosis with Thrombocytopenia Syndrome (TTS) in very rare cases.
- The acknowledgment came amidst legal actions in the UK where individuals affected by TTS have sought compensation.
- Despite the rare risk, health experts and regulatory bodies continue to assert that the benefits of the vaccine outweigh the potential risks.
- Covishield, widely used in India, has been administered to a vast majority of the population with minimal reports of severe side effects.
- The World Health Organization and other health authorities maintain that the vaccine is safe and effective for all adults.
NDTV 
Blaze Media 